Literature DB >> 7544049

Most of the VP1 unique region of B19 parvovirus is on the capsid surface.

M Kawase1, M Momoeda, N S Young, S Kajigaya.   

Abstract

B19 parvovirus is pathogenic in man and a vaccine is desirable. In convalescence after acute infection, the dominant humoral immune response is directed to the minor capsid protein called VP1, which differs from the major capsid protein by an additional NH2-terminal 227 amino acids. We have previously shown that this unique region contains multiple linear neutralizing epitopes. We produced seven recombinant B19 capsids that contained progressively truncated VP1 unique region sequences, each fused to a Flag peptide (AspTyrLysAspAspAspAspLys) at the NH2-terminus. Capsids containing normal VP2 and truncated Flag-VP1 proteins and, in some cases, only truncated Flag-VP1 chimeric proteins, were analyzed by ELISA, affinity chromatography, and electron microscopy using anti-Flag monoclonal antibody. All regions examined showed binding to anti-Flag antibody in multiple assays, indicating that most of the VP1 unique region is external to the capsid and accessible to antibody binding. These results have implications for the design of a B19 parvovirus vaccine and the use of empty capsids for presentation of heterologous protein antigens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544049     DOI: 10.1006/viro.1995.1418

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity.

Authors:  Ning Zhi; Ian P Mills; Jun Lu; Susan Wong; Claudia Filippone; Kevin E Brown
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Visualization of the externalized VP2 N termini of infectious human parvovirus B19.

Authors:  Bärbel Kaufmann; Paul R Chipman; Victor A Kostyuchenko; Susanne Modrow; Michael G Rossmann
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

3.  Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.

Authors:  Joshua C Grieger; Richard J Samulski
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity.

Authors:  Carlos Ros; Marco Gerber; Christoph Kempf
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

5.  Modest truncation of the major capsid protein abrogates B19 parvovirus capsid formation.

Authors:  M Kawase; M Momoeda; N S Young; S Kajigaya
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

6.  Human bocavirus capsid structure: insights into the structural repertoire of the parvoviridae.

Authors:  Brittney L Gurda; Kristin N Parent; Heather Bladek; Robert S Sinkovits; Michael A DiMattia; Chelsea Rence; Alejandro Castro; Robert McKenna; Norm Olson; Kevin Brown; Timothy S Baker; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

7.  The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection.

Authors:  Maija Vihinen-Ranta; Dai Wang; Wendy S Weichert; Colin R Parrish
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Phospholipase A2 activity-dependent stimulation of Ca2+ entry by human parvovirus B19 capsid protein VP1.

Authors:  Adrian Lupescu; C-Thomas Bock; Philipp A Lang; Susanne Aberle; Heike Kaiser; Reinhard Kandolf; Florian Lang
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

Review 9.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

10.  The structure of human parvovirus B19.

Authors:  Bärbel Kaufmann; Alan A Simpson; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.